Pre- and postsynaptic dopamine SPECT in idiopathic parkinsonian diseases: A follow-up study

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Jakobson Mo, Susanna ^a   Linder, Jan ^a   Forsgren, Lars ^a   Holmberg, Henrik ^b   Larsson, Anne ^a   Riklund, Katrine ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; IODINE 123; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DOPAMINE TRANSPORTER; PYRROLIDINE DERIVATIVE;

AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE UPTAKE; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; MALE; PARKINSON DISEASE; PATIENT SELECTION; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; PROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CASE CONTROL STUDY; METABOLISM; PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; SCINTISCANNING; SHY DRAGER SYNDROME; SYNAPSE; TIME;

AGED; BENZAMIDES; CASE-CONTROL STUDIES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FOLLOW-UP STUDIES; HUMANS; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PYRROLIDINES; SUPRANUCLEAR PALSY, PROGRESSIVE; SYNAPSES; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84885633285     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/143532     Document Type: Article

References (44)

1. Poewe W., Wenning G., The differential diagnosis of Parkinson's disease. European Journal of Neuroscience 2002 9 23 30 (Pubitemid 35471980)
2. Hughes A. J., Daniel S. E., Lees A. J., Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001 57 8 1497 1499 2-s2.0-0035940582 (Pubitemid 32995738)
3. Hughes A. J., Daniel S. E., Ben-Shlomo Y., Lees A. J., The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002 125 4 861 870 2-s2.0-0036209085 (Pubitemid 34279780)
4. Dickson D. W., Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harbor Perspectives in Medicine 2012 2 8 a009258 10.1101/cshperspect. a009258
5. Catafau A. M., Tolosa E., Laloux P., Vander Borght T., Van Zandijcke M., De Geeter F., Destee A., Steinling M., Lacomblez L., Habert M.-O., Weiller C., Clausen M., Bogdahn U., Haass A., Kirsch C.-M., Antonini A., Benti R., Sorbi S., Pupi A., Cunha L., de Lima J.P. J. P., Vallderiola F., Lomeña F., Kulisevsky J., Catafau A. M., Weeks R., Buxton-Thomas M., Gibb W. R. G., Kemp P. M., Asenbaum S., Dudczak R., Impact of dopamine transporter SPECT using123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Movement Disorders 2004 19 10 1175 1182 2-s2.0-7244225004 10.1002/mds.20112 (Pubitemid 39433368)
6. Loøkkegaard A., Werdelin L. M., Friberg L., Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. European Journal of Nuclear Medicine 2002 29 12 1623 1629 2-s2.0-1842836514 10.1007/s00259-002-0938-7
7. Vlaar A. M. M., van Kroonenburgh M. J. P. G., Kessels A. G. H., Weber W. E. J., Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurology 2007 7, article 27 2-s2.0-35948961138 10.1186/1471-2377-7-27 (Pubitemid 350066529)
8. Videbaek C., Toska K., Scheideler M. A., Paulson O. B., Moos Knudsen G., SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors. Synapse 2000 38 338 342
9. Burn D. J., Jaros E., Multiple system atrophy: cellular and molecular pathology. Journal of Clinical Pathology 2001 54 6 419 426 2-s2.0-0035666667 (Pubitemid 34025258)
10. Hierholzer J., Cordes M., Venz S., Schelosky L., Harisch C., Richter W., Keske U., Hosten N., Mäurer J., Poewe W., Felix R., Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. Journal of Nuclear Medicine 1998 39 6 954 960 2-s2.0-0031839601 (Pubitemid 28270107)
11. Kim Y. J., Ichise M., Ballinger J. R., Vines D., Erami S. S., Tatschida T., Lang A. E., Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Movement Disorders 2002 17 2 303 312 2-s2.0-0036523783 10.1002/mds.10042 (Pubitemid 36041299)
12. Plotkin M., Amthauer H., Klaffke S., Kühn A., Lüdemann L., Arnold G., Wernecke K.-D., Kupsch A., Felix R., Venz S., Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. Journal of Neural Transmission 2005 112 5 677 692 2-s2.0-17844398549 10.1007/s00702-004-0208-x (Pubitemid 40591200)
13. Vlaar A. M. M., De Nijs T., Kessels A. G. H., Vreeling F. W., Winogrodzka A., Mess W. H., Tromp S. C., Van Kroonenburgh M. J. P. G., Weber W. E. J., Diagnostic value of 123I-ioflupane and 123I- iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes. European Neurology 2008 59 5 258 266 2-s2.0-42449133404 10.1159/000115640 (Pubitemid 351561095)
14. Hellwig S., Amtage F., Kreft A., Buchert R., Winz O. H., Vach W., [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012 79 1314 1322
15. Pirker W., Djamshidian S., Asenbaum S., Gerschlager W., Tribl G., Hoffmann M., Brücke T., Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β -CIT SPECT study. Movement Disorders 2002 17 1 45 53 2-s2.0-0036460924 10.1002/mds.1265 (Pubitemid 36041259)
16. Nocker M., Seppi K., Donnemiller E., Virgolini I., Wenning G. K., Poewe W., Scherfler C., Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I] β -CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging 2012 38 1012 1020 2-s2.0-84858968001 10.1007/s00259-012-2100-5
17. Linder J., Stenlund H., Forsgren L., Incidence of Parkinson's disease and Parkinsonism in northern Sweden: a population-based study. Movement Disorders 2010 25 3 341 348 2-s2.0-77649147743 10.1002/mds.22987
18. Gilman S., Low P. A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C. J., Kaufmann H., Klockgether T., Lang A. E., Lantos P. L., Litvan I., Mathias C. J., Oliver E., Robertson D., Schatz I., Wenning G. K., Consensus statement on the diagnosis of multiple system atrophy. Journal of the Neurological Sciences 1999 163 1 94 98 2-s2.0-0033081705 10.1016/S0022-510X(98)00304-9 (Pubitemid 29155424)
19. Litvan I., Agid Y., Calne D., Campbell G., Dubois B., Duvoisin R. C., Goetz C. G., Golbe L. I., Grafman J., Growdon J. H., Hallett M., Jankovic J., Quinn N. P., Tolosa E., Zee D. S., Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 1996 47 1 1 9 2-s2.0-8944226575 (Pubitemid 26243849)
20. Gibb W. R. G., Lees A. J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1988 51 6 745 752 2-s2.0-0023898945
21. Tomlinson C. L., Stowe R., Patel S., Rick C., Gray R., Clarke C. E., Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders 2010 25 15 2649 2653 2-s2.0-78349261173 10.1002/mds.23429
22. Mo S. J., Linder J., Forsgren L., Larsson A., Johansson L., Riklund K., Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 11 2154 2164 2-s2.0-77958466799 10.1007/s00259-010- 1520-3
23. Larsson A., Mo S. J., Riklund K., Rotation radius dependence of 123I-FP-CIT and 123I-IBZM SPECT uptake ratios: a Monte Carlo study. Journal of Nuclear Medicine Technology 2012 40 249 254
24. Oh M., Kim J. S., Kim J. Y., Shin K.-H., Park S. H., Kim H. O., Moon D. H., Oh S. J., Chung S. J., Lee C. S., Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. Journal of Nuclear Medicine 2012 53 3 399 406 2-s2.0-84858596910 10.2967/jnumed.111.095224
25. Alves G., Larsen J. P., Emre M., Wentzel-Larsen T., Aarsland D., Changes in motor subtype and risk for incident dementia in Parkinson's disease. Movement Disorders 2006 21 8 1123 1130 2-s2.0-33748357972 10.1002/mds.20897 (Pubitemid 44336596)
26. Halliday G. M., Holton J. L., Revesz T., Dickson D. W., Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica 2011 122 2 187 204 2-s2.0-79960842310 10.1007/s00401-011-0852-9
27. Brucke T., Djamshidian S., Bencsits G., Pirker W., Asenbaum S., Podreka I., SPECT and PET imaging of the dopaminergic system in Parkinson's disease. Journal of Neurology, Supplement 2000 247 supplement 4 2 7 2-s2.0-0033817173
28. Van Royen E., Verhoeff N. F. L. G., Speelman J. D., Wolters E. C., Kuiper M. A., Janssen A. G. M., Multiple system atrophy and progressive supranuclear palsy: diminished striatal D2 dopamine receptor activity demonstrated by123I-IBZM single photon emission computed tomography. Archives of Neurology 1993 50 5 513 516 2-s2.0-0027258719 (Pubitemid 23143144)
29. Verstappen C. C. P., Bloem B. R., Haaxma C. A., Oyen W. J. G., Horstink M. W., Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. European Journal of Nuclear Medicine and Molecular Imaging 2007 34 4 502 507 2-s2.0-33947239285 10.1007/s00259-006-0258-4 (Pubitemid 46426986)
30. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A. R., Bioulac B., Brotchie J. M., Gross C. E., Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. Journal of Neuroscience 2001 21 17 6853 6861 2-s2.0-0035449393 (Pubitemid 32781128)
31. Schulz J. B., Klockgether T., Petersen D., Jauch M., Muller-Schauenburg W., Spieker S., Voigt K., Dichgans J., Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. Journal of Neurology Neurosurgery and Psychiatry 1994 57 9 1047 1056 2-s2.0-0028659025
32. Brooks D. J., Ibanez V., Sawle G. V., Playford E. D., Quinn N., Mathias C. J., Lees A. J., Marsden C. D., Bannister R., Frackowiak R. S. J., Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Annals of Neurology 1992 31 2 184 192 2-s2.0-0026612088
33. Brooks D. J., Diagnosis and management of atypical Parkinsonian syndromes. Neurology in Practice 2002 72 1 i10 i16 2-s2.0-0036186158
34. Quinn N., Multiple system atrophy: the nature of the beast. Journal of Neurology Neurosurgery and Psychiatry 1989 52 78 89 2-s2.0-0024474837 (Pubitemid 19167883)
35. Fuxe K., Ferré S., Genedani S., Franco R., Agnati L. F., Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiology and Behavior 2007 92 1-2 210 217 2-s2.0-34548535812 10.1016/j.physbeh.2007.05.034 (Pubitemid 47381380)
36. Ferré S., Quiroz C., Orru M., Guitart X., Navarro G., Cortés A., Adenosine A(2A) Receptors and A(2A) Receptor Heteromers as Key Players in Striatal Function. Frontiers in Neuroanatomy 2011 5, article 36
37. Ferre S., Von Euler G., Johansson B., Fredholm B. B., Fuxe K., Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proceedings of the National Academy of Sciences of the United States of America 1991 88 16 7238 7241 2-s2.0-0025768754 (Pubitemid 21915125)
38. Nevalainen N., Af Bjerkén S., Lundblad M., Gerhardt G. A., Strömberg I., Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia. Journal of Neurochemistry 2011 118 1 12 23 2-s2.0-80052541116 10.1111/j.1471-4159.2011.07292.x
39. Chotibut T., Apple D. M., Jefferis R., Salvatore M. F., Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake. PLoS ONE 2012 7 e52322
40. Scherfler C., Seppi K., Donnemiller E., Goebel G., Brenneis C., Virgolini I., Wenning G. K., Poewe W., Voxel-wise analysis of [123I] β -CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005 128 7 1605 1612 2-s2.0-21944438870 10.1093/brain/awh485 (Pubitemid 41373679)
41. Benarroch E. E., Schmeichel A. M., Low P. A., Parisi J. E., Involvement of medullary serotonergic groups in multiple system atrophy. Annals of Neurology 2004 55 3 418 422 2-s2.0-1442329304 10.1002/ana.20021 (Pubitemid 38269594)
42. Tada M., Kakita A., Toyoshima Y., Onodera O., Ozawa T., Morita T., Nishizawa M., Takahashi H., Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain 2009 132 7 1810 1819 2-s2.0-67650021251 10.1093/brain/awp110
43. Sato K., Kaji R., Matsumoto S., Nagahiro S., Goto S., Compartmental loss of striatal medium spiny neurons in multiple system atrophy of Parkinsonian type. Movement Disorders 2007 22 16 2365 2370 2-s2.0-38549169452 10.1002/mds.21732 (Pubitemid 351155982)
44. Hughes A. J., Daniel S. E., Kilford L., Lees A. J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology Neurosurgery and Psychiatry 1992 55 3 181 184 2-s2.0-0026514953